Xarelto® (rivaroxoaban), a joint product developed by Johnson & Johnson's Janssen Pharmaceuticals subsidiary and Bayer HealthCare, is an anticoagulant that came on the market in 2011. Like other drugs in its class, Xarelto has been linked to uncontrolled bleeding events that have resulted in the need for emergency hospitalizations and blood transfusions and, in some cases, has been linked to patient deaths. People who have been injured by bleeding problems associated with Xarelto may be entitled to financial compensation. The pharmaceutical product liability lawyers at Ury & Moskow, LLC are reviewing potential lawsuits for individuals who have experienced severe bleeding problems while using Xarelto.
Ury & Moskow, LLC may be able to help get compensation for individuals who have experienced:
- Internal Bleeding or Gastrointestinal Bleeding
- Brain Hemorrhage
- Hemorrhagic Stroke
- Wrongful Death From Bleeding Problems
To learn whether you, a friend, or family member may have a Xarelto case against the drug makers, please contact the pharmaceutical product liability lawyers at Ury & Moskow, LLC for a free consultation and claim evaluation.
Xarelto Bleeding Problems
Millions of people have used the anticoagulant Xarelto to reduce the risk of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and other blood clot injuries. It has also been widely prescribed as a post-surgical therapeutic treatment to individuals with non-valvular atrial fibrillation. While all blood thinners carry a risk of internal bleeding, Xarelto may be associated with a much greater risk than the manufacturers indicated in warnings provided for consumers and the medical community.
The manufacturers of Xarelto, Johnson & Johnson, and Bayer promoted the drug as a superior alternative to warfarin (Coumadin) which has been the go-to anticoagulation therapy for decades. Xarelto does not have an approved reversal agent, however, which means that in many cases, bleeding problems cannot be controlled by physicians. Although the drug makers highlight that Xarelto requires less frequent monitoring than warfarin, important information about the lack of an effective Xarelto reversal agent and that individual patients may experience variable reactions to Xarelto which may be undiscovered without proper blood tests has not been properly disclosed.
Xarelto warnings fail to properly address the risk of these serious and fatal bleeding problems, despite a substantial number of adverse event reports. In addition to the inadequate warnings, Xarelto does not appear to provide sufficient benefits to justify the additional risks. In other words, the risks associated with Xarelto appear to exceed any benefits the drug may have, particularly where there is another, safer alternative.
Claims raised in the Xarelto litigation are similar to many of the allegations brought against Boehringer Ingelheim over their related anticoagulant, Pradaxa®.
Following the filing of thousands of lawsuits over failure to warn about the risk of bleeding problems with Pradaxa, Boehringer Ingelheim agreed to pay more than $650 million in mid-2014 to resolve the litigation. Similar compensation may be available through Xarelto settlements, as it appears that Bayer and Johnson & Johnson also withheld important safety information about their drug.
Xarelto Law Suits
Among the allegations raised in Xarelto injury lawsuits being pursued by individuals nationwide, plaintiffs claim Johnson & Johnson and Bayer:
- Failed to properly study, investigate, and test Xarelto and its risk of bleeds.
- Failed to develop a reversal agent to stop Xarelto-related bleeds.
- Fail to provide accurate warnings about the risk of Xarelto bleeds.
- Withhold information about the lack of an effective Xarelto reversal agent.
- Engage in aggressive marketing that encourage doctors to use the more expensive and more dangerous drug without adequate monitoring.
- Sell an unreasonably dangerous and defective drug as it was initially formulated.
- Fail to update warnings, issue a "Dear Doctor" letter, or issue an Xarelto recall even after it has become clear that a large number of users were suffering severe and life-threatening injuries from uncontrollable bleeding.
- Rather than withdrawing Xarelto from the market or taking steps to ensure accurate information was provided for consumers and the medical community, Johnson & Johnson and Bayer continue to promote the medication as safe and effective, causing millions of additional individuals to be exposed to a risk of serious injury.
The makers of Xarelto put profits over consumers' safety by failing to properly research the risk of bleeds associate with Xarelto and failing to properly warn about the serious and potentially life-threatening health problems that may be caused by Xarelto use. Xarelto is now projected to be the 19th best-selling drug in the world by 2018, with sales expected to reach $3.7 billion per year.
Xarelto Product Liability Lawyers Seek to Protect People, Not Profits
The pharmaceutical product liability lawyers at Ury & Moskow, LLC are reviewing potential lawsuits for individuals who have experienced severe bleeding problems while using Xarelto.